UroGen Pharma
URGN • NASDAQ
UroGen Pharma is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Elizabeth A. Barrett, with a market cap of $835.9M.
CEOElizabeth A. Barrett
Next Earnings
Upcoming earnings announcement for UroGen Pharma
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.53
Revenue Estimate
$43.8M
Earnings History
Past 12 earnings reports for UroGen Pharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Q4 2025 | -$0.54Est: -$0.57 | +5.3% | $37.8MEst: $38.2M | -0.9% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.69Est: -$0.70 | +1.4% | $27.5MEst: $31.9M | -13.7% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$1.05Est: -$0.83 | -26.5% | $24.2MEst: $23.7M | +2.3% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.92Est: -$0.80 | -15.0% | $20.3MEst: $22.7M | -10.8% | 10-Q |
| Mar 10, 2025 | Q4 2024 | -$0.80Est: -$0.72 | -11.1% | $24.6MEst: $25.3M | -2.7% | 10-K/A |
| Nov 6, 2024 | Q3 2024 | -$0.55Est: -$0.82 | +32.9% | $25.2MEst: $24.2M | +4.1% | 10-Q |
| Aug 13, 2024 | Q2 2024 | -$0.91Est: -$0.84 | -8.3% | $21.8MEst: $23.8M | -8.0% | 10-Q |
| May 13, 2024 | Q1 2024 | -$0.97Est: -$0.87 | -11.5% | $18.8MEst: $21.4M | -12.2% | 10-Q |
| Mar 14, 2024 | Q4 2023 | -$0.72Est: -$0.68 | -5.9% | $23.5MEst: $22.6M | +4.3% | 10-K/A |
| Nov 14, 2023 | Q3 2023 | -$0.68Est: -$0.85 | +20.0% | $20.9MEst: $20.0M | +4.1% | — |
| Aug 10, 2023 | Q2 2023 | -$1.03Est: -$1.14 | +9.6% | $21.1MEst: $20.1M | +5.1% | — |
| May 11, 2023 | Q1 2023 | -$1.30Est: -$1.33 | +2.3% | $17.2MEst: $17.2M | +0.1% | — |